Payment overview · 2025
General Payments
$299.75
6 reported records · 2 companies
Healthcare provider profile · identity verified
David K Lauer, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · WICHITA, KS · NPI 1336257427
Verified facts
What the public records show
CMS Open Payments records show David K Lauer, M.D. received $299.75 in general payments during 2025 across 6 reported records.
Medtronic, Inc. accounted for 50.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 5 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Symbicort by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$151.44 | 50.5% | 4 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $148.31 | 49.5% | 2 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $299.75 | 6 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $148.31 | 2 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $128.00 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $128.00 | 1 | 2025 |
Source payment records
|
|||||
| INTELLIS ADAPTIVESTIM Normalized: intellis adaptivestim |
Device | Medtronic, Inc. | $78.27 | 3 | 2025 |
Source payment records
|
|||||
| SYMPLICITY G3 Normalized: symplicity g3 |
Device | Medtronic, Inc. | $73.17 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Prednisone | Prednisone | 343 | 228 |
| Atorvastatin Calcium | Atorvastatin Calcium | 293 | 65 |
| Levothyroxine Sodium | Levothyroxine Sodium | 281 | 68 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 280 | 54 |
| Amlodipine Besylate | Amlodipine Besylate | 261 | 55 |
| Lisinopril | Lisinopril | 259 | 61 |
| Omeprazole | Omeprazole | 259 | 63 |
| Escitalopram Oxalate | Escitalopram Oxalate | 236 | 32 |
| Meloxicam | Meloxicam | 234 | 66 |
| Pantoprazole Sodium | Pantoprazole Sodium | 220 | 56 |
| Zolpidem Tartrate | Zolpidem Tartrate | 179 | 29 |
| Tramadol Hcl | Tramadol Hcl | 177 | 52 |
| Metformin Hcl Er | Metformin Hcl | 168 | 37 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 164 | 37 |
| Gabapentin | Gabapentin | 163 | 27 |
| Warfarin Sodium | Warfarin Sodium | 150 | 15 |
| Potassium Chloride | Potassium Chloride | 142 | 39 |
| Tamsulosin Hcl | Tamsulosin Hcl | 126 | 40 |
| Furosemide | Furosemide | 120 | 36 |
| Simvastatin | Simvastatin | 118 | 31 |
| Metoprolol Succinate | Metoprolol Succinate | 113 | 23 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 112 | 28 |
| Metformin Hcl | Metformin Hcl | 112 | 25 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 111 | 31 |
| Citalopram Hbr | Citalopram Hydrobromide | 109 | 17 |
| Lorazepam | Lorazepam | 105 | 33 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 105 | 24 |
| Quetiapine Fumarate | Quetiapine Fumarate | 105 | 18 |
| Cefdinir | Cefdinir | 104 | 83 |
| Celecoxib | Celecoxib | 93 | 18 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 92 | 24 |
| Fluticasone Propionate | Fluticasone Propionate | 90 | 30 |
| Glimepiride | Glimepiride | 89 | 17 |
| Sertraline Hcl | Sertraline Hcl | 89 | 17 |
| Azithromycin | Azithromycin | 84 | 71 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 82 | 28 |
| Hydrochlorothiazide | Hydrochlorothiazide | 80 | 19 |
| Amoxicillin | Amoxicillin | 79 | 54 |
| Alprazolam | Alprazolam | 75 | 17 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 73 | 55 |
| Allopurinol | Allopurinol | 66 | 15 |
| Pregabalin | Pregabalin | 66 | 17 |
| Amitriptyline Hcl | Amitriptyline Hcl | 64 | 12 |
| Metoprolol Tartrate | Metoprolol Tartrate | 64 | 15 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 55 | 40 |
| Spironolactone | Spironolactone | 54 | 13 |
| Doxycycline Hyclate | Doxycycline Hyclate | 51 | 34 |
| Trazodone Hcl | Trazodone Hcl | 51 | suppressed |
| Clonazepam | Clonazepam | 50 | 13 |
| Clopidogrel | Clopidogrel Bisulfate | 50 | 14 |
| Duloxetine Hcl | Duloxetine Hcl | 48 | suppressed |
| Levofloxacin | Levofloxacin | 48 | 39 |
| Eliquis | Apixaban | 47 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 46 | 11 |
| Ozempic | Semaglutide | 46 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 44 | 35 |
| Fluconazole | Fluconazole | 44 | 18 |
| Bupropion Xl | Bupropion Hcl | 43 | suppressed |
| Estradiol | Estradiol | 42 | 13 |
| Pioglitazone Hcl | Pioglitazone Hcl | 41 | suppressed |
| Cephalexin | Cephalexin | 40 | 31 |
| Temazepam | Temazepam | 38 | suppressed |
| Atenolol | Atenolol | 37 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 37 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 37 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 36 | suppressed |
| Losartan Potassium | Losartan Potassium | 36 | 11 |
| Pravastatin Sodium | Pravastatin Sodium | 36 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 36 | 24 |
| Synthroid | Levothyroxine Sodium | 36 | suppressed |
| Methocarbamol | Methocarbamol | 35 | 11 |
| Irbesartan | Irbesartan | 34 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 33 | suppressed |
| Nifedipine Er | Nifedipine | 32 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 32 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 31 | suppressed |
| Carvedilol | Carvedilol | 30 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 30 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 30 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 29 | suppressed |
| Klor-Con M20 | Potassium Chloride | 27 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 27 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 26 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 25 | 15 |
| Ibuprofen | Ibuprofen | 24 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 24 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 22 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 22 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 21 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 21 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 21 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 20 | suppressed |
| Minocycline Hcl | Minocycline Hcl | 20 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 19 | 17 |
| Glipizide Er | Glipizide | 19 | suppressed |
| Xarelto | Rivaroxaban | 19 | suppressed |
| Baclofen | Baclofen | 18 | suppressed |
| Chlorthalidone | Chlorthalidone | 18 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 18 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 18 | suppressed |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 18 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 16 | suppressed |
| Insulin Syringe | Syringe And Needle,insulin,1ml | 16 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 16 | 16 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 16 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 16 | suppressed |
| Bumetanide | Bumetanide | 15 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 15 | suppressed |
| Fenofibrate | Fenofibrate | 15 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 15 | suppressed |
| Ondansetron Odt | Ondansetron | 15 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 15 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 15 | suppressed |
| Glipizide | Glipizide | 14 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 14 | suppressed |
| Jardiance | Empagliflozin | 14 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 14 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 14 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 14 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 13 | suppressed |
| Butorphanol Tartrate | Butorphanol Tartrate | 13 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 13 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 13 | suppressed |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 13 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 13 | suppressed |
| Trulicity | Dulaglutide | 13 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Diazepam | Diazepam | 12 | suppressed |
| Eszopiclone | Eszopiclone | 12 | suppressed |
| Januvia | Sitagliptin Phosphate | 12 | suppressed |
| Livalo | Pitavastatin Calcium | 12 | suppressed |
| Mirtazapine | Mirtazapine | 12 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 12 | suppressed |
| Torsemide | Torsemide | 12 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 12 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 11 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 11 | suppressed |
| Linzess | Linaclotide | 11 | suppressed |
| Metronidazole | Metronidazole | 11 | suppressed |
| Nystatin | Nystatin | 11 | suppressed |
| Olanzapine | Olanzapine | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $299.75 · 6 records | Medtronic, Inc. | AIRSUPRA, BREZTRI, FARXIGA, INTELLIS ADAPTIVESTIM, SYMPLICITY G3 | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error